TEVA PHARMACEUTICAL INDUSTRIES LTD Amortization of Intangible Assets in USD from 2011 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.
Summary
Teva Pharmaceutical Industries Ltd quarterly/annual Amortization of Intangible Assets history and growth rate from 2011 to Q3 2025.
  • Teva Pharmaceutical Industries Ltd Amortization of Intangible Assets for the quarter ending September 30, 2025 was $144M, a 1.37% decline year-over-year.
  • Teva Pharmaceutical Industries Ltd Amortization of Intangible Assets for the twelve months ending September 30, 2025 was $581M, a 1.19% decline year-over-year.
  • Teva Pharmaceutical Industries Ltd annual Amortization of Intangible Assets for 2024 was $588M, a 4.55% decline from 2023.
  • Teva Pharmaceutical Industries Ltd annual Amortization of Intangible Assets for 2023 was $616M, a 15.8% decline from 2022.
  • Teva Pharmaceutical Industries Ltd annual Amortization of Intangible Assets for 2022 was $732M, a 8.73% decline from 2021.
Amortization of Intangible Assets, Trailing 12 Months (USD)
Amortization of Intangible Assets, Quarterly (USD)
Amortization of Intangible Assets, YoY Quarterly Growth (%)
Amortization of Intangible Assets, Annual (USD)
Amortization of Intangible Assets, YoY Annual Growth (%)

TEVA PHARMACEUTICAL INDUSTRIES LTD Quarterly Amortization of Intangible Assets (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $581M $144M -$2M -1.37% Jul 1, 2025 Sep 30, 2025 10-Q 2025-11-05
Q2 2025 $583M $148M +$2M +1.37% Apr 1, 2025 Jun 30, 2025 10-Q 2025-07-30
Q1 2025 $581M $145M -$7M -4.61% Jan 1, 2025 Mar 31, 2025 10-Q 2025-05-07
Q4 2024 $588M $144M $0 0% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-05
Q3 2024 $588M $146M +$1M +0.69% Jul 1, 2024 Sep 30, 2024 10-Q 2025-11-05
Q2 2024 $587M $146M -$16M -9.88% Apr 1, 2024 Jun 30, 2024 10-Q 2025-07-30
Q1 2024 $603M $152M -$13M -7.88% Jan 1, 2024 Mar 31, 2024 10-Q 2025-05-07
Q4 2023 $616M $144M -$11M -7.1% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-05
Q3 2023 $627M $145M -$20M -12.1% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-06
Q2 2023 $647M $162M -$50M -23.6% Apr 1, 2023 Jun 30, 2023 10-Q 2024-07-31
Q1 2023 $697M $165M -$35M -17.5% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $732M $155M -$33M -17.6% Oct 1, 2022 Dec 31, 2022 10-K 2025-02-05
Q3 2022 $765M $165M -$34M -17.1% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-09
Q2 2022 $799M $212M +$39M +22.5% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-02
Q1 2022 $760M $200M -$42M -17.4% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q4 2021 $802M $188M -$74M -28.2% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-12
Q3 2021 $876M $199M -$52M -20.7% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-03
Q2 2021 $928M $173M -$76M -30.5% Apr 1, 2021 Jun 30, 2021 10-Q 2022-07-27
Q1 2021 $1B $242M -$16M -6.2% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-03
Q4 2020 $1.02B $262M -$28M -9.66% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-10
Q3 2020 $1.05B $251M -$4M -1.57% Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-27
Q2 2020 $1.05B $249M -$36M -12.6% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-28
Q1 2020 $1.09B $258M -$25M -8.83% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-28
Q4 2019 $1.11B $290M +$33M +12.8% Oct 1, 2019 Dec 31, 2019 10-K 2022-02-09
Q3 2019 $1.08B $255M -$42M -14.1% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-05
Q2 2019 $1.12B $285M -$17M -5.63% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 $1.14B $283M -$27M -8.71% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-07
Q4 2018 $1.17B $257M -$99M -27.8% Oct 1, 2018 Dec 31, 2018 10-K 2021-02-10
Q3 2018 $1.27B $297M -$60M -16.8% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-07
Q2 2018 $1.33B $302M -$108M -26.3% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 $1.43B $310M -$11M -3.43% Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-02
Q4 2017 $1.44B $356M -$637M -64.1% Oct 1, 2017 Dec 31, 2017 10-K 2020-02-21
Q3 2017 $2.08B $357M -$454M -56% Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-01
Q2 2017 $2.54B $410M Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-02
Q1 2017 $321M Mar 30, 2017 Mar 31, 2017 6-K 2017-05-11
Q4 2016 $993M +$155M +18.5% Dec 30, 2016 Dec 31, 2016 6-K 2017-11-02
Q3 2016 $811M Sep 29, 2016 Sep 30, 2016 6-K 2016-11-15
Q4 2015 $838M Dec 30, 2015 Dec 31, 2015 6-K 2016-11-15

TEVA PHARMACEUTICAL INDUSTRIES LTD Annual Amortization of Intangible Assets (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $588M -$28M -4.55% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-05
2023 $616M -$116M -15.8% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-05
2022 $732M -$70M -8.73% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-05
2021 $802M -$218M -21.4% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-12
2020 $1.02B -$93M -8.36% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-10
2019 $1.11B -$53M -4.55% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-09
2018 $1.17B -$278M -19.3% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-10
2017 $1.44B +$451M +45.4% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-21
2016 $993M +$155M +18.5% Jan 1, 2016 Dec 31, 2016 10-K 2018-02-12
2015 $838M -$198M -19.1% Jan 1, 2015 Dec 31, 2015 10-K 2018-02-12
2014 $1.04B -$144M -12.2% Jan 1, 2014 Dec 31, 2014 20-F 2017-02-15
2013 $1.18B -$92M -7.23% Jan 1, 2013 Dec 31, 2013 20-F 2016-02-11
2012 $1.27B +$565M +79.9% Jan 1, 2012 Dec 31, 2012 20-F 2015-02-09
2011 $707M Jan 1, 2011 Dec 31, 2011 20-F 2014-02-10
* An asterisk sign (*) next to the value indicates that the value is likely invalid.